In Silico Optimization of Ewingella americana Oncolytic Therapy: Mitigating Hepatic Clearance and Sepsis Risks via a pH-Sensitive "Stealth-Swarm" Liposomal Delivery System

The attached document is a scientific proposal and simulation study authored by Dr. Tshibangu Kabanga. It presents a computational solution to optimize a novel cancer therapy using the bacterium Ewingella americana. Here is a detailed description of the article's contents: 1. Core Problem: The "Allometric Gap" The paper addresses a critical failure in translating recent findings by Iwata et al. regarding Ewingella americana from murine (mouse) models to human application. Through in silico Physiological Based Pharmacokinetic (PBPK) modeling of 50,000 virtual human patients, the author identifies two major barriers to standard intravenous delivery: The "Liver Trap": Human hepatic macrophages (Kupffer cells) clear over 85% of the bacteria within 45 minutes, preventing therapeutic accumulation in the tumor. Sepsis Risk: Humans are significantly more sensitive to endotoxins than mice, leading to a high risk of cytokine storms at effective doses. 2. Methodology: Digital Twin Simulation The study utilizes a "Holistic System Modeling Engine (MMSH)" to create Digital Twins of Stage IV Colorectal and Pancreatic cancer patients. The simulation tested two scenarios: Scenario A (Standard IV): Resulted in sub-therapeutic tumor doses and severe hepatotoxicity in 88% of subjects. Scenario B ("Omega" Protocol): The proposed encapsulated delivery system. 3. Proposed Solution: The "Omega Protocol" The author proposes a "Stealth-Swarm" vector—a computationally designed, pH-sensitive liposomal delivery system. Key features include: Lipid Architecture: A mix of DOPE, CHEMS, and DSPE-PEG2000 designed to be stable in blood (pH 7.4) but unstable in the acidic tumor microenvironment (pH < 6.5). Mechanism: Evasion: A PEG "stealth" layer prevents immune detection, bypassing the liver. Release: The bacteria are released via passive acidification in the tumor or active triggering by Focused Ultrasound (FUS). Results: Simulation data predicts this method restores tumor colonization to >99% while dropping systemic toxicity risk to <0.5%. 4. Safety Protocol The paper includes a mandatory "Kill Switch" safety measure. Since E. americana remains sensitive to Ciprofloxacin, the protocol requires administering this antibiotic at the first sign of systemic inflammation to abort the therapy within 45 minutes. Conclusion The document concludes that the "Omega Protocol" offers a validated path to bypass physiological bottlenecks that typically cause bacteriotherapies to fail in Phase I trials, and invites in vivo validation of the vector.